Dr. Ethan Russo, a neurologist often profiled in Cannabis Culture for his work on behalf of the healing herb, has organized an all-day symposium on Cannabinoids in Pain Management to be presented on Saturday September 28, 2002 in Reno, Nevada as part of the annual American Academy of Pain Management meeting.
Here is the schedule of international experts scheduled to present information about cannabinoid therapeutics.
Please contact Dr. Russo via email at firstname.lastname@example.org for more information.
8:00-9:00 AM: John McPartland, DO: Progress in Neurobiology Related to Cannabinoids
Dr. McPartland is an osteopath and the Programme Developer at UNITEC School of Health Science, Auckland, New Zealand. He is the author of Hemp Diseases and Pests, and innumerable articles on cannabis. He will be speaking on the cannabinoid receptor system, phytocannabinoids, and their role in pain modulation, and relevance to clinicians.
9:05-10:05 AM: Ethan Russo, MD: Cannabis: From Raw Plant to Pharmaceutical Products
Dr. Russo is a child and adult neurologist and researcher, with faculty appointments at the Univ. of Montana, and Univ. of Washington. He is the author of Handbook of Psychotropic Herbs, numerous articles on cannabis, and editor of the Journal of Cannabis Therapeutics and co-editor of Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential. He will present a brief history of cannabis in pain and its biochemical basis, as well as the process of growing cannabis clones, isolating its various components, and processing them for use as prospective prescription products.
10:20-11:20 AM: David Hadorn, MD: Trial Designs for Cannabinoids
Dr. Hadorn is former health policy adviser to the New Zealand Ministry of Health and the British Columbia Ministry of Health, as well as consultant to GW Pharmaceuticals. He will present information on the development of the GW Pharmaceuticals clinical research program in the United Kingdom. Topics will include advantages of phytocannabinoids over synthetics, pharmacokinetics of Cannabis-Based Medicine Extracts (CBME), and the structure of clinical trials employing them.
11:25-12:25 PM: William Notcutt, MD: Results from Cannabis-Based Medicine Extract Trials
Dr. Notcutt is an anesthesiologist and pain management specialist at Norwich University (UK), with long experience in treatment of pain with cannabinoids. He will present the results to date in 200 patient-years of data amassed in Phase II trials of cannabis-based medicine extracts in chronic pain and multiple sclerosis, benefits seen in a spasticity, mobility, sleep, mood, and bladder function, as well as encountered adverse events.
1:55-2:55 PM: Mark Ware, MD: Canadian Cannabis: Grants, Trials and Outcomes
Dr. Ware is a pain management specialist at McGill University in Montreal, Quebec, Canada, and heads the Canadian Consortium for the Investigation of Cannabinoids (CCIC). He will discuss the current state of research in Canada, the Medicinal Cannabis Access Program in association with Health Canada, and therapeutic applications of cannabis, particularly to neuropathic pain.
3:00-4:00 PM: Igor Grant, MD David Hadorn, MD: Current and Planned Trials
Dr. Grant is professor of psychiatry at the University of California San Diego and Director of the University of California Center for Medicinal Cannabis Research (CCMCR). In this session, he will discuss current trials underway with smoked cannabis in HIV, neuropathic pain and other indications, as well as how clinicians can approach the gauntlet of federal agencies to pursue clinical cannabis research.
Dr. Hadorn will address the therapeutic potential of non-psychoactive cannabinoids, such as cannabidiol (CBD), combinations of cannabinoids with opiates in pain management, future planned clinical trials with inflammatory gastrointestinal disorders and other indications, and the applications of GW Pharmaceuticals’ Advanced Delivery System (ADS) which may revolutionize research and administration of opiates and other sensitive medications.
A Conference Announcement is available as follows:
A Conference Brochure is available as follows:
Of course, full Continuing Education credits for a variety of disciplines are available for this meeting. We hope you will consider joining us. If you are not able to attend, we hope that you will explore other available sources of information on the topic, including the Journal of Cannabis Therapeutics: